clinical trial · NCT05896228
Iberdomide, Daratumumab, Carfilzomib, and Dexamethasone (Iber-KDd) in Patients With Relapsed/Refractory Multiple Myeloma
Benjamin T Diamond, MD·phase2·recruiting·n = 30
Refractory Multiple MyelomaRelapsed Multiple MyelomaIberdomideCarfilzomibDaratumumabDexamethasoneAcetaminophenDiphenhydramineMontelukast
brief summary
The investigators want to find out whether or not giving patients who have relapsed or refractory multiple myeloma (MM) the experimental medication combination iberdomide, carfilzomib, daratumumab, and dexamethasone (Iber-KDd) may produce better results than the current (standard of care) treatments. This study will examine the tolerability and efficacy of this combination therapy for all participants and the ability of this combination therapy to shrink or prevent MM from returning.
started
Feb 20, 2024
primary completion
Mar 1, 2029
completion
Mar 1, 2031
last updated
Mar 11, 2026
official title
Phase 2, Single-Arm Study of Iberdomide, Daratumumab, Carfilzomib, and Dexamethasone (Iber-KDd) in Patients With Relapsed/Refractory Multiple Myeloma
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol